Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors

April 15, 2016
Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1
Conference|Annual Meeting of the American Radium Society (ARS)

Differences in the legal needs of economically and geographically diverse patients with cancer suggest that those needs are not determined solely by disease state but that they also correspond with geographic and economic characteristics.

Serguei A. Castaneda, MD, Tomas Bednar, JD, MA, Roderick Price, MS, Lydia Komarnicky-Kocher, MD; Department of Radiation Oncology, Cancer Center, Hahnemann University Hospital and Drexel University College of Medicine

BACKGROUND: Medical-legal partnerships (MLPs) identify and serve the legal needs of vulnerable patient populations. The specific legal needs of patients with cancer in urban hospitals are not completely characterized.

OBJECTIVE: To identify the legal needs of a group of patients from our cancer center, and the relationship between these needs and geography and income.

METHODS: We collected de-identified data on legal needs and demographic variables in 94 patients. We stratified patients into three groups, according to their income: (1) above the national average (> $53,046), (2) below the national average but above Medicaid eligibility for a family of three ($27,310–$53,046), and (3) below the line of Medicaid eligibility (< $27,310). We then compared the legal needs of these three subgroups with those of the total patient population.

RESULTS: Fifty-four percent of patients from the poorest zip codes showed a primary interest in income management and public benefits compared with 37% of the total population, whereas 47% of those from the most affluent areas had the strongest interest in advanced planning documents compared with 29% of the total population. In contrast, those from the middle-income group had a seemingly even distribution of needs compared with the total population. Needs related to consumer/employment (24%) and Medicaid/Medicare (22%) were distributed somewhat uniformly across the three subgroups. Furthermore, patients from the affluent zip codes identified needs in only five out of eight categories, leaving out housing, utilities, and miscellaneous, whereas the other two groups identified issues in nearly all of the categories.

CONCLUSIONS: Differences in the legal needs of economically and geographically diverse patients with cancer suggest that those needs are not determined solely by disease state but that they also correspond with geographic and economic characteristics. MLPs could help to anticipate and serve the specific legal needs of patients in urban cancer centers and possibly even patients with cancer in general. 

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
Related Content
Advertisement

While metastasis-directed therapy has shown it may be a tool for prolonging PFS in other research, progression does still occur in most patients.

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

Tim Cortese
September 29th 2025
Article

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.

PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer

Russ Conroy
September 29th 2025
Article

Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.

Thoracic Consolidation Plus SBRT to Cranial Mets May Improve OS in ES-SCLC

Roman Fabbricatore
September 24th 2025
Article

In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.


The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma

Roman Fabbricatore
September 22nd 2025
Article

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

Related Content
Advertisement

While metastasis-directed therapy has shown it may be a tool for prolonging PFS in other research, progression does still occur in most patients.

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

Tim Cortese
September 29th 2025
Article

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.

PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer

Russ Conroy
September 29th 2025
Article

Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.

Thoracic Consolidation Plus SBRT to Cranial Mets May Improve OS in ES-SCLC

Roman Fabbricatore
September 24th 2025
Article

In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.


The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma

Roman Fabbricatore
September 22nd 2025
Article

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.